Management of Heart Failure: ESC Updates Guidelines
Written By : Dr. Kamal Kant Kohli
Published On 2023-08-28 04:30 GMT | Update On 2023-08-28 11:14 GMT
Advertisement
Canada: The European Society of Cardiology (ESC) has taken a significant stride in the field of heart failure management with a focused update to their heart failure guidelines. This update incorporates crucial data from nearly a dozen new clinical trials that have been published since 2021. The trials include notable studies such as EMPEROR-Preserved, DELIVER, STRONG-HF, IRONMAN, and more. The updated guidelines, which were unveiled on the opening day of the ESC Congress 2023, offer novel recommendations related to the use of SGLT2 inhibitors in patients with heart failure and updates on comorbidity management.
New Recommendations:
- SGLT2 Inhibitors for Heart Failure with Reduced Ejection Fraction (HFmrEF) and Preserved Ejection Fraction (HFpEF): The guidelines now recommend the use of SGLT2 inhibitors (dapagliflozin or empagliflozin) in patients with HFmrEF and HFpEF. This is to reduce the risk of heart failure hospitalization or cardiovascular death. The recommendation is classified as Class I, Level A, signifying a strong endorsement based on robust evidence.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.